NanoValent Pharmaceuticals Inc.

NanoValent was incorporated in 2006 to commercialize the Polymerized Liposomal Nanoparticle (PLN) drug delivery technology. The Company focuses on custom drug delivery and drug targeting solutions for insoluble, toxic, or unstable drug molecules using novel nanoparticle formulations.

NanoValent

Currently developing nanoparticle therapies for:

- Multi-Drug Resistant Tumors

- siRNA loaded nanoparticles for Neuoroblastoma

- SN38 loaded nanoparticles for Ewing's Sarcoma

-Nanoparticle based Yersinia pestis vaccines

-siRNA loaded nanoparticles forAcute Lymphoblastic Leukemia

NanoValent has nanoparticle R&D partnerships with the following institutions:

-Kettering Hospital: Nanoparticle imaging applications

-Children's Hospital Los Angeles: Nanoparticle siRNA delivery

-National Institute of Health: Nanoparticle siRNA delivery

-University of Texas at Houston: Nanoparticle drug delivery

-Novelix Pharmaceuticals Inc.: Nanoparticle drug delivery

What's New?

• NanoValent to provide nanoparticles for Novelix drug delivery projects.
• NanoValent Partners with University of Texas to supply nanoparticles and nano-rods for drug delivery studies.
• NanoValent Enters into siRNA delivery partnership with NIH targeting Neuroblastoma
• NanoValent acquires 11 enabling nanoparticle drug delivery patents.
• NanoValent awarded NanoVaccine nanoparticle patent.
• NanoValent enters into siRNA nanoparticle delivery development project with Children's Hospital Los Angeles.
• NanoValent to develop nanoparticle therapy for Ewings Sarcoma in conjuction with Childrens Hospital Los Angeles.